Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 7, 2017June 7, 2017

Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

News, rheumatoid arthritis

Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according to results of a Phase ... Read more

March 8, 2017March 8, 2017

Cytokine IL-21 Fuels Inflammation at Synovial Joints in RA Patients, Study Shows

News, rheumatoid arthritis

Scientists have discovered a group of immune cells that cause joint inflammation in rheumatoid arthritis (RA) by secreting a factor called interleukin (IL)-21 — a potential new target for RA therapeutics. The study ... Read more

January 27, 2017January 27, 2017

Real-time Imaging Used to Identify Protein That Triggers Inflammatory Arthritis

News

Using a novel imaging technique, researchers followed in real time the movement of immune cells in a live mouse and identified a key factor responsible for triggering inflammatory arthritis. The ... Read more

December 2, 2016December 2, 2016

Specific Fibroblasts Found to Promote Joint Damage in RA, Study Shows

News, rheumatoid arthritis

Researchers at the University of Birmingham in England unraveled the key role of different types of fibroblasts — cells that synthesize extracellular matrix and collagen — in rheumatoid arthritis (RA). The study, ... Read more

November 7, 2016November 7, 2016

Baricitinib Enhances RA Patients’ Outcomes in Phase 3 Trial

News

Patients with rheumatoid arthritis (RA) and inadequate responses to biological disease-modifying antirheumatic drugs (bDMARDs) show a positive response to treatment with baricitinib (LY3009104), with the therapy improving several patient-reported outcomes, ... Read more

October 3, 2016October 3, 2016

Potential RA Therapy, CT-P10, Seen in Study to Be Biosimilar to Rituxan

News

In a Phase 1 clinical trial, researchers showed that CT-P10 is a biosimilar to Rituxan (rituximab), a current treatment of choice for rheumatoid arthritis (RA) patients who fail to respond to ... Read more

August 17, 2016August 17, 2016

Heart Attack Risk for RA Patients Linked to C-Reactive Protein

News

Rheumatoid arthritis (RA) patients who present high levels of inflammation markers have an increased risk for myocardial infarction (heart attack) according to the study “Impact of disease activity and treatment of comorbidities ... Read more

August 10, 2016August 10, 2016

Cell Therapy Seen in Trial to Benefit RA Patients Who Don’t Respond to Biologics

News

Mesoblast has announced positive results of a Phase 2 clinical trial evaluating its lead mesenchymal precursor cell (MPC) therapy candidate, MPC-300-IV, in people with biologic refractory rheumatoid arthritis (RA). “The safety and ... Read more

August 8, 2016August 8, 2016

MicroRNA May Offer Way to Control T-cells in RA and Other Autoimmune Diseases

News

An international collaboration involving researchers at The Scripps Research Institute (TSRI) unveiled the role a small molecule called microRNA-155 (miR-155) plays in our immune system, a finding that could help scientists develop novel therapies ... Read more

July 29, 2016July 29, 2016

In Rheumatoid Arthritis Patients, Immunotherapy Appears to Reduce Cardiovascular Risk

News

Patients with rheumatoid arthritis (RA) treated with an immunotherapy of low-dose combination of two anticytokines have a reduced disease activity and a lower risk for cardiac events, according to researchers. These findings ... Read more